Aroa Biosurgery Limited (ASX:ARX)
Australia · Delayed Price · Currency is AUD | Market Cap | 179.87M -32.3% |
| Revenue (ttm) | 86.47M +22.6% |
| Net Income | 3.89M |
| EPS | 0.01 |
| Shares Out | 345.90M |
| PE Ratio | 48.42 |
| Forward PE | 40.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,462 |
| Open | 0.5300 |
| Previous Close | 0.5250 |
| Day's Range | 0.5200 - 0.5300 |
| 52-Week Range | 0.4750 - 0.8000 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 1.07 (+105.77%) |
| Est. Earnings | Oct 29, 2026 |
About Aroa Biosurgery
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, p... [Read more]
Analyst Summary
According to 3 analysts, the average rating for ARX stock is "Strong Buy." The 12-month stock price target is $1.07, which is an increase of 105.77% from the latest price.
News
Aroa Biosurgery Transcript: Study result
In the RCT, Symphony improved 12-week wound closure and shortened healing time versus standard care, with similar overall adverse-event rates and fewer infections. Evidence is being used to support payer coverage amid outpatient market disruption.
Aroa Biosurgery Slides: Study result
Aroa Biosurgery has posted slides in relation to its latest quarterly earnings report, which was published on October 11, 2026.
Aroa Biosurgery Transcript: Status update
The MASTRR interim analysis covered 474 complex defects and found no definitively device-related adverse events, with a 0.7% deep tissue infection rate. Management positioned the real-world evidence as a commercial differentiator as Myriad continued to grow.
Aroa Biosurgery Slides: Status update
Aroa Biosurgery has posted slides in relation to its latest quarterly earnings report, which was published on October 6, 2026.
Aroa Biosurgery Transcript: AGM 2026
Revenue grew 23% to NZD 104 million, driven by Myriad’s strong performance and expanding direct sales. Board changes and strategic investments in sales infrastructure support future growth, while Ovitex and Symphony face market challenges but offer significant long-term potential.
Aroa Biosurgery Slides: FY 2026
Aroa Biosurgery has posted slides in relation to its FY 2026 quarterly earnings report, which was published on August 18, 2026.
Aroa Biosurgery Earnings Call Transcript: H2 2026
Revenue grew 23% to NZD 104 million, driven by Myriad's 54% growth and high margins. Profitability and strong cash flow were achieved, with significant investments planned for sales expansion and Symphony's market opportunity. FY 2027 guidance targets 13%–23% revenue growth.
Aroa Biosurgery Earnings release: H2 2026
Aroa Biosurgery released its H2 2026 earnings on May 25, 2026, summarizing the period's financial results.
Aroa Biosurgery Slides: H2 2026
Aroa Biosurgery has posted slides in relation to its H2 2026 quarterly earnings report, which was published on May 25, 2026.
Aroa Biosurgery Annual report: H2 2026
Aroa Biosurgery has published its H2 2026 annual report on May 25, 2026.
Aroa Biosurgery Earnings Call Transcript: Q3 2026
Clinical and commercial momentum is strong, with Myriad outperforming in trauma and Symphony poised to benefit from US reimbursement changes. FY26 revenue and EBITDA are tracking toward the upper end of guidance, with ongoing profitability and positive cash flow.
Aroa Biosurgery Earnings release: Q3 2026
Aroa Biosurgery released its Q3 2026 earnings on February 2, 2026, summarizing the period's financial results.
Aroa Biosurgery Slides: Q3 2026
Aroa Biosurgery has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 2, 2026.
Aroa Biosurgery Earnings Call Transcript: H1 2026
Revenue grew 13% YoY to $44.9M with positive EBITDA and strong cash flow. Myriad sales surged 33%, and Tela Bio expanded its commercial team and product pipeline. CMS reimbursement changes may disrupt competitors, creating new opportunities.
Aroa Biosurgery Quarterly report: H1 2026
Aroa Biosurgery has published its H1 2026 quarterly earnings report on November 24, 2025.
Aroa Biosurgery Slides: H1 2026
Aroa Biosurgery has posted slides in relation to its H1 2026 quarterly earnings report, which was published on November 24, 2025.
Aroa Biosurgery Earnings release: H1 2026
Aroa Biosurgery released its H1 2026 earnings on November 24, 2025, summarizing the period's financial results.